Preprint Review Version 1 This version is not peer-reviewed

Management of Myasthenia Gravis During COVID-19 Pandemic

Version 1 : Received: 6 June 2020 / Approved: 7 June 2020 / Online: 7 June 2020 (09:28:09 CEST)

How to cite: Wu, X.; Yuan, J.; Karim, M.R.; Wang, Y. Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints 2020, 2020060074 (doi: 10.20944/preprints202006.0074.v1). Wu, X.; Yuan, J.; Karim, M.R.; Wang, Y. Management of Myasthenia Gravis During COVID-19 Pandemic. Preprints 2020, 2020060074 (doi: 10.20944/preprints202006.0074.v1).

Abstract

The outbreak of COVID-19 has brought unprecedented risks and challenges to everyone in the world. Myasthenia gravis is an autoimmune disease of the nervous system. Infection can worsen it and cause severe symptoms such as myasthenia crisis and respiratory failure. At present, the pandemic of COVID-19 may promote the aggravation of patients with MG. This article focuses on the respiratory management of MG patients during the epidemic of COVID-19.

Subject Areas

COVID-19; myasthenia gravis; respiratory management

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.